TMEM220-AS1: A Potential Drug Target and Biomarker (G101101775)

Target Name: TMEM220-AS1

NCBI ID: G101101775

TMEM220-AS1

Other Name(s): TMEM220 antisense RNA 1 | TMEM220 antisense RNA 1, transcript variant 4 | TMEM220-AS1 variant 4

TMEM220-AS1: A Potential Drug Target and Biomarker

TMEM220-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. Its function is not well understood, but it is known to be involved in the regulation of cellular processes that are essential for the survival and proper functioning of tissues. There is growing interest in studying TMEM220-AS1 as a potential drug target and biomarker due to its unique structure and the potential impact it may have on various diseases.

The TMEM220-AS1 Protein

TMEM220-AS1 is a member of the transmembrane protein family, which means it spans the cell membrane and is involved in various cellular processes. It has a unique structure that consists of a transmembrane domain and an intracellular domain. The transmembrane domain is responsible for the protein's ability to interact with other molecules on the cell surface, while the intracellular domain is responsible for its ability to interact with cells within the body.

TMEM220-AS1 is expressed in a variety of tissues and cells, including the brain, heart, liver, and kidneys. It is also involved in the regulation of cellular processes that are essential for the survival and proper functioning of these tissues. For example, TMEM220-AS1 has been shown to be involved in the regulation of ion channels, which are responsible for the flow of electrical current through cells. It has also been shown to be involved in the regulation of signaling pathways that are involved in inflammation and cellular proliferation.

Potential Drug Target

TMEM220-AS1 is a potential drug target due to its unique structure and the functions it is involved in. One of the main advantages of targeting TMEM220-AS1 is its potential impact on various diseases. For example, TMEM220-AS1 has been shown to be involved in the regulation of ion channels, which are involved in the pathophysiology of many diseases, including epilepsy, Alzheimer's disease, and Parkinson's disease.

Targeting TMEM220-AS1 may also have potential benefits in treating certain types of cancer, as it has been shown to be involved in the regulation of cell signaling pathways that are involved in cancer growth and progression. Additionally, TMEM220-AS1 may also be a potential biomarker for certain types of cancer, as its expression has been shown to be associated with the development of certain types of cancer.

Biomarker Potential

TMEM220-AS1 may also be a potential biomarker for various diseases due to its unique expression and the functions it is involved in. For example, TMEM220-AS1 has been shown to be involved in the regulation of cellular processes that are essential for the survival and proper functioning of tissues, which may be relevant to a variety of diseases.

Conclusion

TMEM220-AS1 is a protein that is expressed in various tissues of the body and is involved in the regulation of cellular processes that are essential for the survival and proper functioning of tissues. As a potential drug target and biomarker, TMEM220-AS1 is a promising target for the development of new therapies for a variety of diseases. Further research is needed to fully understand its functions and potential as a drug target and biomarker.

Protein Name: TMEM220 Antisense RNA 1

The "TMEM220-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM220-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets